Andreia Yuri Yoshigae
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andreia Yuri Yoshigae has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Cesar Souza Castilho
University of Western São Paulo (UNOESTE), Presidente Prudente, São Paulo, Brazil
1 shared publication - Ariana Musa de Aquino
São Paulo State University (UNESP)
1 shared publication - Beatriz Díaz-Fabregat
Graduate Program in Dentistry, University of Western São Paulo (UNOESTE), Presidente Prudente, Brazil
1 shared publication - Juliane Avansini Marsicano
Universidade do Oeste Paulista, Brasil
1 shared publication - Juliano Pelim Pessan
Department of Pediatric Dentistry and Public Health, School of Dentistry, São Paulo State University (UNESP), Araçatuba 16015-050, SP, Brazil
1 shared publication - Leonardo de Oliveira Mendes
Graduate Program in Animal Science, Western São Paulo University (UNOESTE), Presidente Prudente, Brazil
1 shared publication
Latest Publications
- 5 October 2021
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 74 (6) , 1917-1926
Are Serum Ferritin Levels a Reliable Cancer Biomarker? A Systematic Review and Meta-Analysis
Although serum ferritin (SF) has been shown in several studies to be a potential cancer biomarker, the results are inconsistent. Herein, a systematic review was performed to investigate the clinical SF levels in different types of tumors in order to verify the role of SF levels as a biomarker for cancer diagnosis. The search was performed using the PubMed/Medline, Cochrane Library, and Scopus databases. Observational studies comparing SF levels between healthy adults and patients with cancer were included. The meta-analysis was carried out according to the inverse variance and random effects model. The standardized mean differences (SMDs) were assessed at 95% confidence intervals (CIs). We found that SF was higher in patients with cancer (SMD 3.07; CI 1.96,4.17), especially for head and neck cancer (SMD 3.88; CI 0.42,7.34), lung cancer (SMD 1.72; CI 0.67,2.78), pancreatic cancer (SMD 6.79; CI 5.66,7.91), and renal cell carcinoma (SMD 1.77; CI 0.48,3.05). Moreover, in the advanced stages (Stages III and IV), ferritin levels were higher than in healthy adults (SMD 4.89; CI 2.72,7.06, and SMD 8.40; CI 6.99,9.82, respectively). SF acts as a biomarker for pancreatic cancer, renal cell carcinoma, lung cancer, and head and neck cancer and is a sensitive biomarker for the detection of advanced stages of tumors.
- 5 October 2021
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 74 (6) , 1917-1926
Are Serum Ferritin Levels a Reliable Cancer Biomarker? A Systematic Review and Meta-Analysis
Although serum ferritin (SF) has been shown in several studies to be a potential cancer biomarker, the results are inconsistent. Herein, a systematic review was performed to investigate the clinical SF levels in different types of tumors in order to verify the role of SF levels as a biomarker for cancer diagnosis. The search was performed using the PubMed/Medline, Cochrane Library, and Scopus databases. Observational studies comparing SF levels between healthy adults and patients with cancer were included. The meta-analysis was carried out according to the inverse variance and random effects model. The standardized mean differences (SMDs) were assessed at 95% confidence intervals (CIs). We found that SF was higher in patients with cancer (SMD 3.07; CI 1.96,4.17), especially for head and neck cancer (SMD 3.88; CI 0.42,7.34), lung cancer (SMD 1.72; CI 0.67,2.78), pancreatic cancer (SMD 6.79; CI 5.66,7.91), and renal cell carcinoma (SMD 1.77; CI 0.48,3.05). Moreover, in the advanced stages (Stages III and IV), ferritin levels were higher than in healthy adults (SMD 4.89; CI 2.72,7.06, and SMD 8.40; CI 6.99,9.82, respectively). SF acts as a biomarker for pancreatic cancer, renal cell carcinoma, lung cancer, and head and neck cancer and is a sensitive biomarker for the detection of advanced stages of tumors.